Table 2.

Prevalence of Ever Discussed Both Advantages and Disadvantages of Prostate-Specific Antigen Testing Among Men Aged 40 Years and Older Who Had the Test Within the Past Year, National Health Interview Survey, 2015

	Ever Discussed Advantages and Disadvantages^*
	N^{^†}	%	95% CI	P value
Total	1955	31.0	28.1–34.1
Who first suggested the PSA test				.061
Patient or someone else	287	25.1	19.0–32.3
Physician	1668	32.0	28.9–35.4
40 to 54 years	373	28.2	22.1–35.2
Who first suggested the PSA test				.771
Patient or someone else	74	26.2	14.6–42.5
Physician	299	28.6	21.8–36.5
55 to 69 years	1003	34.8	30.8–39.1
Who first suggested the PSA test				.006
Patient or someone else	148	23.6	16.1–33.2
Physician	855	36.8	32.4–41.3
70+ years	579	26.0	21.8–30.6
Who first suggested the PSA test				.830
Patient or someone else	65	27.3	16.0–42.6
Physician	514	25.8	21.3–30.8

PSA, prostate-specific antigen testing; CI, confidential interval.
↵* Status of “Ever discussed advantages and disadvantages” was assessed based on two survey questions: (1) Did a doctor ever talk with you about the advantages of the test?; and (2) Did a doctor ever talk with you about the disadvantages of the test.
↵† Number may differ from the total of 2024 because of “don't know,” refused, or missing responses.